Febuxostat for mild to moderate ulcerative colitis
Treatments studied
Part of Digestive system clinical trials.
This trial tests if adding febuxostat to your usual mesalamine treatment can help improve mild to moderate ulcerative colitis. It's for adults with confirmed UC who are not on steroids or other immune-suppressing drugs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have mild to moderate ulcerative colitis, confirmed by a scope exam.
- You are currently taking mesalamine (5-ASA) for your UC.
- You are not on steroids (pills or enemas), immunosuppressants, or biologic drugs.
- You do not have diabetes, liver disease, severe heart problems, or other active inflammatory diseases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests adding a medicine called mebendazole (normally used for parasites) to standard mesalamine treatment for people with mild or moderate ulcerative colitis. The goal is to see if it helps control inflammation better than mesalamine alone.
This trial tests whether adding alpha lipoic acid (an antioxidant) to your usual mesalamine treatment helps control mild to moderate ulcerative colitis. It is for people newly diagnosed and not on other UC treatments.
This trial tests a new treatment for people with ulcerative colitis (UC) whose disease is active despite taking only mesalamine or sulfasalazine. It aims to find a therapy that can reduce inflammation and improve symptoms.
This trial studies whether an oral treatment called MS-20 can improve ulcerative colitis (UC) in adults with moderate to severe disease. You may be asked to provide stool samples from home and avoid certain foods and medicines before screening and during the study.
This study tests whether adding acupuncture (using small intradermal needles) to the standard medication mesalazine improves outcomes for people with mild-to-moderate ulcerative colitis. Participants receive 12 acupuncture sessions and undergo two colonoscopies to assess the treatment's effect.
This study tests whether taking tofacitinib alone works as well as taking tofacitinib with mesalamine for people with ulcerative colitis who are already in remission. It aims to see if one medication can be stopped without causing a flare-up.
Hear when a new Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.